

4TH INTERNATIONAL CONFERENCE ON SANFILIPPO SYNDROME AND RELATED DISEASES

DAY 1 - THURSDAY, NOVEMBER 13, 2025

09:15

Introduction and welcome

Stylios Antonorakis

Gene Therapy and ERT

09:30 - 10:00

OTL-201 – A Clinical Study of the Investigational Haematopoietic Stem Cell Gene Therapy in MPSIIIA.

Prof. Brian Bigger (UK)

10:00 - 10:30

Combination of HSPC transplantation and cathepsin B inhibitors for treatment of Sanfilippo disease.

Prof. Alexey Pshezhetsky (CAN)

10:30 - 11:00 BREAK

11:00 - 11:30

Preclinical validation of an intravenous AAV gene therapy for mucopolysaccharidosis IIIB.

Pr. Jerome Ausseil (FR)

11:30 - 12:00

JR-441 – An intravenous enzyme replacement therapy to deliver the sulfamidase enzyme to the brain to treat Sanfilippo type A.

Dr Nicole Muschol, UKE Hamburg (DE)

12:00 - 12:30

MPS IIIC Gene Replacement Therapy with scAAV9/ HGSNAT Vector, JLK-247.

Phoenix Nest (US) Speaker Jill Wood on behalf of Xin Chen

12:30 LUNCH

Gene Therapy and ERT continued

14:00 - 14:30

Investigational Therapies for Sanfilippo Syndrome and Related MPS Disorders: Denali Therapeutics' Enzyme Transport Vehicle (ETV) Platform and Clinical Updates.

Denali Therapeutics (US)

14:30 - 15:00

Long-term intracerebroventricular treatment with Tralesinidase Alfa (AX 250) for Sanfilippo type B.

Dr Nicole Muschol, UKE Hamburg (DE)

15:00 - 15:30 BREAK

Sanfilippo Symptoms and Natural History

15:30 - 16:00

The role of the inflammasome and systemic inflammation in neurologic progression of Sanfilippo disease.

Brian Bigger (UK)

16:00 - 16:30

Leveraging Remote Video Capture in MPS IIIC and IIID Natural History Studies: Introducing C-RARE for Real-World Evidence to Support Clinical Trial Treatment Efficacy.

Phoenix Nest (US) Speaker: Jill Wood

16:30 - 17:30

Combining Therapeutic Approaches for Sanfilippo treatment (Participants based on attendees present)

Scientific Round Table Discussion



4TH INTERNATIONAL CONFERENCE ON SANFILIPPO SYNDROME AND RELATED DISEASES

DAY 2 - FRIDAY, NOVEMBER 14, 2025

Novel Therapies and Approaches

08:30 - 09:00

Harnessing the power of deep learning to repurpose drugs for the treatment of the Sanfilippo syndrome. Dr. Anna Fournier, Swiss Data Science Center with the Fondation Sanfilippo Suisse (CH)

09:00 - 09:30

Targeting protein amyloids and brain autophagy-lysosomal pathway in Sanfilippo Syndrome and other neuronopathic MPSs.

Alessandro Fraldi (IT)

09:30 - 10:00

VRO073 – A novel molecule for the potential treatment of GM1, GM2 gangliosidosis and Gaucher Disease type 3.

Dr Vincent Mutel, Dorphan SA (SUI)

10:00 - 10:30 BREAK

Screening, Biomarkers and Animal Models

10:30 - 11:00

Assessment of a central nervous system demyelination in Sanfilippo disease by diffusion tensor imaging: a non-invasive method to evaluate disease progression and therapeutic response.

Prof. Alexey Pshezhetsky (CAN)

11:00 - 11:30

Biomarkers, diagnostic testing and drug development for Sanfilippo Syndrome and other MPS diseases.

Prof. Peter Bauer, Centogene (DE)

11:30 - 12:00

The effect of treatment with a heparanase-inhibiting polysaccharide on the MPS III A mouse model.

Stéphane Sizonenko (CH)

12:00 - 12:45

Family Q&A Session

Open questions and answers for families

12:45

Closing Remarks and Conference Wrap-up

13:00 LUNCH

_